

To: Keystone First/Keystone First Community HealthChoices (CHC) Provider

Date: April 5, 2024

Re: Important Update – Flovent Removal

As we previously communicated in December 2023, GlaxoSmithKline recently discontinued manufacturing of brand name Flovent Diskus and Flovent HFA. These products have remained Preferred on the Pennsylvania Department of Human Services (DHS) Statewide Preferred Drug List (PA PDL) that is utilized by all managed care organizations (MCOs), as some supply remained on pharmacy shelves. However, effective April 4, 2024, these products are now designated as “Non-Preferred” by DHS on the PA PDL.

Per direction from Pennsylvania DHS, current utilizers of brand name Flovent Diskus and Flovent HFA will be allowed to continue utilizing these medications without prior authorization. However, we strongly encourage you to work with your Members/Participants that utilize these products to identify appropriate alternatives on the PA PDL and to transition to these alternatives as soon as possible. Once current supply in the marketplace has been exhausted, these products will be completely inaccessible, regardless of PA PDL status or previous utilization by Members/Participants.

Please consider the following as you work with your Members/Participants on transitioning away from brand name Flovent products:

Product Name	FDA-approved Age	PA PDL Preferred Alternatives	FDA-approved Age
Flovent Diskus	4 years and older	Asmanex Twisthaler	4 years and older
		QVAR Redihaler	
Flovent HFA		Asmanex HFA	5 years and older
		Arnuity Ellipta	
		Pulmicort Flexhaler	6 years and older

For a complete list of Preferred and Non-preferred drugs to be included in the 2024 Statewide PDL, as well as any limits associated with these drugs, please visit <https://papdl.com>.

If you have any questions regarding this change, please contact Keystone First Pharmacy Services at **1-800-588-6767** or Keystone First CHC Pharmacy Services at **1-866-907-7088**.